🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 19, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, logistics, services), proxy season dominates with 20+ DEF 14A/DEFA14A filings for AGMs clustered in April-May 2026, emphasizing board elections, say-on-pay, and auditor ratifications amid neutral sentiment. Financial performance is polarized: standout YoY revenue growth in retail/logistics (Five Below +22.9% to $4.76B, FedEx Q3 +8% to $24B, Firefly Aerospace +163% to $159.9M) and industrials (Cardinal Infrastructure +45% to $456M, York Space +52% to $386M), contrasted by declines (FiscalNote FY25 -21% to $95.4M, Crawford -2.3% to $1.31B) and widening losses (Larimar Q4 $62.5M vs prior $28.8M). Capital allocation trends positive with buybacks (Aflac $3.5B/33M shares, Crawford $10.5M up from $3.9M), dividend hikes (Aflac +5.2% to $0.61 Q1 2026, Crawford +3.6% to $0.29), and debt reductions (Crawford -24.8% to $151M, Wolfspeed refinancing $475.9M higher-cost notes). Forward guidance largely raised/affirmed (FedEx FY26 rev growth to 6-6.5%, Firefly $420-450M, Cardinal 20%+ EBITDA margin), signaling resilience in consumer demand despite margin pressures (e.g., Cardinal gross margin -80bps to 14%). M&A/JV activity bullish (UniFirst-Cintas merger, Horizon $100M JV), with no notable insider transactions but major holders like GAMCO/Saba in funds. Portfolio-level: 8/15 key financial filers show >20% rev growth avg +60%, but 5 report margin compression avg -100bps; actionable now on catalysts like FedEx spin-off.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 19, 2026

Across 45 filings in the USA S&P 500 Healthcare stream, biotech and healthcare firms (e.g., Assembly, SELLAS, Humacyte, Inhibrx) dominate with narrowed net losses (avg -20% YoY across 6 biotechs) amid R&D ramps (+16% avg YoY) and key partnerships like Gilead's $35M HPI license to Assembly, but cash burns persist requiring shelf registrations and offerings. Broader filings reveal mixed revenue trends (+1.6% YoY sales at Signet, -5.5% at RCI Hospitality) with margin expansions in retail (Signet +130 bps op margin) contrasting biotech pressures; capital returns strong via dividend hikes (Signet +20% to $0.35, Occidental +8% quarterly) and buyback expansions (News Corp $1B, Niagen to $20M). Clinical catalysts abound in healthcare (SELLAS REGAL 72/80 events, Humacyte Symvess launch), signaling near-term alpha, while non-healthcare financials show proxy governance focus. Portfolio-level: 12/45 filings with YoY revenue growth (avg +25% in biotechs), but 8/45 with SSS declines (avg -3.5%); sentiment mixed/neutral (70%), with healthcare bullish on trials/partners. Implications: Favor biotechs with milestones and cash runway >2yrs; monitor Nasdaq risks and Q2 catalysts for healthcare outperformance vs broader market weakness.

25 high priority 20 medium 45 total filings
· daily

Global High-Priority Regulatory Events — March 19, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include routine ABS servicing compliance affirmations (20+ filings, all neutral with no material issues), SPAC extensions and merger adjournments signaling prolonged dealflow, accretive M&A in credit funds, positive insolvency resolutions, and stark contrasts in financial performance with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales) versus declines in digital health (DarioHealth -17% revenue). Period-over-period trends show robust revenue acceleration in 7 high-materiality filers averaging +80% YoY (Micron, argenx, Republic Airways), margin expansions flipping losses to profits in 3 cases, but cash burn persists in pre-revenue SPACs and health tech. Critical developments like Mount Logan's $100M+ asset acquisition (30% FRE boost), Rajeswari Infrastructure's insolvency resolution, and Cannabist Co's forbearance extension highlight takeover, bankruptcy, and regulatory risks resolving positively or extending stress. Portfolio-level patterns reveal sector divergence: tech/biotech outperformance amid financing activity (debt, equity offerings), financial pledges/encumbrances signaling liquidity strains in promoters (Embassy 21% shares), and neutral governance updates in proxies. No widespread insider trading patterns, but capital allocation leans toward growth/reinvestment over returns, with scheduled events clustering in Q2 2026 offering catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 19, 2026

Two S-1 IPO registration statements filed on March 19, 2026, highlight an active US IPO pipeline targeting autonomous robotics (Exyn Technologies) and nuclear energy (Eagle Nuclear Energy Corp.), reflecting investor interest in AI-driven autonomy and clean energy transitions amid 2026 market recovery. Exyn demonstrates superior operational metrics with positive sentiment (10/10 materiality), including 35% larger volume capture, 44% reduction in survey time (27 to 15 minutes), 97% faster setup (30 to under 1 minute), and 50% cost savings over 10 years in mining case studies, with thousands of autonomous flights since 2016 at Level 4B SAE autonomy. Eagle Nuclear shows neutral sentiment (9/10 materiality) with no revenue or earnings reported through 2025-12-31, but multiple capital raises via Regulation Crowdfunding (2025-04/05) and Private Placements (2024-2025), alongside uranium properties and heavy related-party involvement. No period-over-period financial trends available across filings, but Exyn's operational outperformance vs traditional methods signals strong pre-IPO momentum; Eagle's SPAC ties and offerings indicate funding access despite lacks. Portfolio-level theme: Early-stage IPOs prioritizing tech innovation over current profitability, with Exyn outperforming on metrics (e.g., 1cm accuracy, 2M data points/sec) relative to Eagle's neutral profile. Market implications include potential sector rotation into autonomy/mining/defense and nuclear revival, warranting watch for pricing catalysts.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — March 19, 2026

Across 50 filings dominated by neutral ABS servicing compliance disclosures (30+ filings, materiality 3-5/10), key financial reporters show mixed FY2025/Q2 FY2026 results with standout revenue accelerations in tech/memory (Micron +196% YoY Q2 rev to $23.9B) and retail (Ollie's +16.6% sales to $2.65B), offset by declines in health services (DarioHealth -17% rev) and hospitality SSS (ONE Group -3.7%). Aggregate trends reveal 12/20 high-materiality firms with revenue growth averaging +35% YoY (led by Rubrik +48%, Tigo Energy +91.7%), but margins mixed with expansions in 6 (e.g., Micron gross to $17.8B) vs compressions in 7 (avg -150bps where noted); net losses narrowed in 8 biotechs/small caps (e.g., Mustang Bio -88% YoY). Cash positions strengthened in 10 firms (avg +40% YoY, e.g., FedEx to $8B), but deteriorated in 7 (e.g., Lithium Americas liabilities +900%). SPACs (Artius II, Rice) standard pre-deal with trust growth but deficits. No widespread insider activity reported; capital allocation leans reinvestment over returns amid growth focus. Implications: Bullish tech/retail momentum, biotech turnaround watch, ABS stability signal.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 19, 2026

Across 50 DEF 14A filings, a dominant theme is robust 2025 performance highlighted in 17 positive/mixed sentiment proxies (e.g., revenue records at Vericel +20% CAGR, Occidental $10.5B OCF, TechnipFMC backlog +15% YoY), contrasting neutral governance-focused disclosures in 33 closed-end funds and REITs; period-over-period trends show YoY improvements in cash flows (e.g., TechnipFMC FCF +113%), dividends (Aflac +5.2%, BorgWarner +55%), and buybacks ($3.5B at Aflac), with rare declines like Aflac net earnings -29.2% YoY and Tronox 60% dividend cut. Capital allocation leans shareholder-friendly with $4.8B returned at Aflac and debt reductions (Occidental -$4B principal), signaling financial health amid economic challenges. Board refreshments are common (e.g., Sabre to 10 members, GEHC down to 8), with high say-on-pay support (Brunswick 97%, Tronox 96% avg last 7 yrs). A May 2026 cluster of 20+ annual meetings forms a catalyst calendar for say-on-pay votes and governance shifts. Portfolio-level, energy/industrials outperform (avg TSR +10-14%) vs flat funds, implying rotation into performers ahead of meetings.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 19, 2026

Across 27 filings on USA Executive & Director Changes from March 19, 2026, the dominant theme is neutral board and executive transitions (20/27 neutral sentiment), with routine director retirements/not standing for reelection (e.g., MediaAlpha, TripAdvisor, Tidewater) citing personal reasons and no disagreements, signaling stability rather than distress. Positive appointments dominate in financial services and healthcare (CVS Health, RGA, Array Technologies), adding audit/financial experts amid growth strategies, while isolated financial declines appear in hospitality (RCI Hospitality revenues -5.5% YoY to $279.4M, Bombshells -29.2% YoY). Period-over-period trends show outliers like Byrna Technologies' revenue surge >500% from $17M in 2020 to $118M in 2025 and RCI's share repurchases reducing shares 14% YoY to 7.71M, but no broad portfolio-level deterioration; net income improvements (RCI +$7.8M YoY) offset revenue softness. Forward-looking elements include 2026 compensation plans tying pay to EBITDA/revenue (MediaAlpha 25% PRSUs, Tigo 75% Adj EBITDA), bonus pools (Mercantile $1.21M target), and multiple 2026 annual meetings as catalysts. Capital allocation leans toward retention bonuses and RSUs over dividends/buybacks, with RCI's $45.4M FCF flat YoY highlighting reinvestment potential. Overall, low materiality (avg 5.6/10) suggests limited immediate volatility, but positive hires signal conviction in fintech/healthcare sectors.

27 high priority 27 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 19, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (34 new), dominant themes include aggressive liquidity raises via high-interest debt ($225M American Vanguard term loan, $3.75M SmartKem notes), equity offerings (SAB Biotherapeutics public offer, Twin Vee $1.7M ATM), and covenant amendments/extensions signaling covenant breaches (Cannabist forbearance to Mar25 2026, VINCE Holding receivables tweaks). Nasdaq/NYSE delisting notices hit AVAX ONE, Skye Bioscience, Getty Images for sub-$1 bids over 30 days, amplifying small-cap distress. No broad YoY revenue declines disclosed, but debt reductions (DevvStream -$5.9M net) and refinancings (Wolfspeed $475.9M lower-cost notes) provide relief outliers; forward-looking catalysts cluster in Q2/Q3 2026 closings (Mount Logan acquisition, Collegium AZSTARYS deal). Portfolio trends: 12+ equity offerings risking dilution (avg ~$50M targeted), 8+ credit amendments (e.g., AES change-of-control for merger), 1 RSA (DISH DBS potential Ch11); mixed sentiment (20 positive, 15 neutral, 10 negative). Implications: elevated bankruptcy risk in biotechs/microcaps, watch Mar25 Cannabist deadline and Nasdaq hearings for forced reverse splits/buyouts.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 19, 2026

Three US-listed companies—AVAX One Technology Ltd. (Nasdaq), Skye Bioscience, Inc. (Nasdaq), and Getty Images Holdings, Inc. (NYSE)—received deficiency notices between March 13-17, 2026, for common stock bid/closing prices below $1.00 for 30 consecutive business/trading days, violating Nasdaq Listing Rules 5550(a)(2)/5450(a)(1) and NYSE Section 802.01C. This represents a uniform 30-day period-over-period price decline trend across all filings, signaling broad weakness in share prices with no YoY/QoQ recovery mentioned. No immediate trading suspensions occurred, but high materiality (9/10) and negative sentiment underscore delisting risks, with AVAX securing a hearing stay, Skye gaining 180 calendar days to September 14, 2026, and Getty a six-month cure period. Forward-looking paths include potential reverse stock splits (explicit for Skye, implied elsewhere) and compliance via 10 consecutive days at or above $1.00, though no assurances provided. Portfolio-level pattern: cross-sector small-cap distress (tech, biotech, media), amplifying volatility and potential OTC transfers. Implications include heightened short interest, dilution risks from splits, and time-sensitive catalysts for investor positioning.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 19, 2026

Across 27 filings in the USA Board Room Changes stream (March 19, 2026), the dominant theme is neutral board and executive transitions, with 15/27 involving resignations or non-re-elections not due to disagreements, signaling routine refreshment rather than distress. Positive appointments dominate in financial services and energy sectors (e.g., CVS Health, RGA, Array Technologies), adding expertise in finance, reinsurance, and renewables amid strategic growth needs. Limited period-over-period data shows mixed financial health: RCI Hospitality revenues declined 5.5% YoY to $279.4M with Adjusted EBITDA down to $52.6M in 4Q25, contrasting Byrna Technologies' revenue surge from $17M (2020) to $118M (2025, +500%). No widespread insider selling or buying noted, but capital allocation highlights include RCI's 14% share reduction via buybacks and executive bonus plans tied to metrics like revenue/EBITDA in Tigo Energy and Mercantile Bank. Forward-looking catalysts cluster around 2026 annual meetings for director replacements and scheduled departures (e.g., Clear Secure GC April 3). Overall, low materiality (avg 5.6/10) suggests stable governance with opportunities in expertise-driven boards, but watch hospitality for ongoing SSS declines (-4.4% 4Q25).

27 high priority 27 total filings
· daily

US Merger & Acquisition SEC Filings — March 19, 2026

The USA M&A & Takeover Activity stream reveals intense SPAC activity across 10/12 filings, with new IPOs (Metals Acquisition Corp II $230M, Praetorian $253M total), over-allotment exercises, and multiple BCA extensions (Pyrophyte 5th amendment to Apr 2027, Blue incentive pool to 8%), signaling prolonged deal hunts amid market appetite for fresh capital. Ashford Hospitality Trust's $56.8M hotel sale drove pro forma revenue decline of 1.5% YoY to $1.15B (YE2024) but improved net loss 17% to $68.5M, reflecting deleveraging. Battalion Oil's all-stock acquisition added 7,090 acres and 30 drilling locations, expanding contiguous holdings 35% to 27,097 acres. No insider trading reported; capital allocation focuses on trust funding (Constellation note to $5.25M) and debt repayment. Period trends show stable/no declines in most SPACs, mixed in hospitality; forward deadlines cluster Q2 2026-Q1 2027, building catalyst calendar. Portfolio-level: 7/12 neutral sentiment, 3 positive IPO/amendments, implying SPAC resilience but extension fatigue risk.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 19, 2026

Across 50 overnight SEC filings, standout revenue accelerations dominate in semiconductors (Micron +196% YoY to $23.9B) and biotech (argenx +90% YoY sales to $4.15B), contrasting with declines in digital health (DarioHealth -17% YoY to $22.4M) and energy (Equinor -2.5% YoY to $43.8B), highlighting sector divergence amid mixed economic signals. Airlines (Republic +13.7% YoY revenue) and solar (SUNation +26% FY to $71.9M, beating guidance) show resilience, while SPACs (Artius II, Rice Acquisition) report trust interest offsetting losses but extended deal timelines signal delays. Capital allocation leans positive with steady dividends (Modiv $0.10/month common, Global Net Lease preferreds) and repurchases (News Corp $1B program), but debt stresses emerge (Cannabist forbearance extension, American Vanguard $225M term loan at SOFR+8.25%). Merger catalysts near (RYVYL 99% votes cast, reconvene 3/25) and routine ABS servicing compliance in 20+ filings indicate stable structured finance. Portfolio trend: 7/15 high-materiality filings show revenue growth >20% YoY averaging +80%, but 4 report cash burn or dilution; implications favor selective longs in semis/biotech pre-open.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 18, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via related filings), proxy statements dominate, signaling peak AGM season in Q2 2026 with 10+ meetings (e.g., Wells Fargo April 28, Primo Brands April 28, Piedmont May 12), emphasizing governance and compensation votes amid stable sector backdrop. Financial reporters show robust revenue growth averaging ~30% YoY (e.g., Accelerant +51.5%, Five Below +22.9% FY25, Envela +33.6%), driven by expansion and M&A, but mixed profitability with margin compressions (Envela -220 bps, PGIM yield -122 bps) and swing losses (Accelerant -$1.35B). Staples highlights include General Mills earnings release and McCormick controller transition (neutral), while Primo Brands post-merger proxy underscores beverage stability. M&A/capital activity surges (FingerMotion acquisition, Energy Fuels ASM deal, Accelerant $200M buyback), but dilution risks in microcaps (Artelo bridge notes, ECD notes). Portfolio trends: 7/12 metric-rich filings report YoY revenue acceleration vs flat/decline in laggards like Actelis (-53%), positioning outperformers for catalysts. Implications: favor growth names with guidance (Five Below FY26 $5.2-5.3B sales), monitor proxies for comp changes, avoid dilution traps.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 18, 2026

Across 50 filings from diverse sectors (heavy in financials despite Industrials focus), overarching themes include robust M&A activity in banking (e.g., Heritage Commerce merger supplements, Independent Bank $70M deal 6% accretive), mixed financial performance with revenue growth in outliers like Tecogen (+19.7% YoY to $27M) and Hills Bancorp (assets +4.5%, net income +27.1%), but margin pressures (Tecogen gross margins -730bps to 36.3%, Home Depot operating income -2.9%). Period-over-period trends show YoY revenue growth averaging ~10% in reporting firms (e.g., Spire FY25 $71.6M, Tecogen +20%), NIM expansions in banks (+67bps at Hills), but widening losses (Tecogen net loss +73% to $8.25M Q4) and flat incomes (Golden Growers +0.3%). Capital allocation leans toward dividends (Great Southern $0.43/share), debt extensions (Hilton RCf maturity extended), and equity issuances for M&A/growth. Critical developments: Advancing acquisitions (Great Lakes HSR cleared), positive guidance (Spire FY26 rev $75-85M, +41-61% ex-maritime), and leadership stability awards (Eagle Bancorp $1.175M continuity pay). Portfolio-level: Industrials subset shows resilient growth amid macro volatility, with M&A catalysts driving near-term upside but litigation risks in deals.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 18, 2026

Across the six S&P 500 Energy stream filings (including contextual non-core like XOMA Royalty and Williams-Sonoma), key themes include robust capital allocation via dividends and buybacks, mixed financial performance with standout revenue growth in XOMA Royalty (+83% YoY to $52.1M) and Williams Companies (Adjusted EBITDA +9% YoY to $7.75B), contrasted by revenue declines at Williams-Sonoma (-4.2% YoY Q4 FY25). Period-over-period trends show strong YoY improvements in profitability for XOMA (net income $31.7M vs $13.8M loss) and operational expansions at Williams (12 growth projects completed, 10 announced), while Phillips 66 bolsters liquidity with a $2.25B term loan. Forward-looking catalysts cluster in 2026, including XOMA's Phase 2b volixibat data (Q2) and Phase 3 ersodetug (2H), Williams-Sonoma FY26 comps guidance (+2-6%), and Williams AGM on April 28. Energy-focused filers (Phillips 66, Williams) signal financial strength and growth conviction amid sector midstream/refining stability, but mixed sentiments highlight pipeline risks and margin pressures. Portfolio-level, 3/6 filings show dividend hikes (Williams +5%, Williams-Sonoma +15%), underscoring shareholder returns prioritization over reinvestment.

3 high priority 3 medium 6 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 18, 2026

Across 50 SEC filings in the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers, and adjacent sectors), overarching themes include robust capital returns via dividends (e.g., Great Southern Bancorp $0.43/share Q1 2026) and buybacks (Vistra $5.75B since 2021, NRG $1.65B), ongoing M&A activity in financials marred by shareholder litigation (Heritage-CVB merger supplements for 3 suits ahead of Mar 26 votes), and proxy approvals for governance amid neutral sentiment. Period-over-period trends reveal mixed revenue performance: 8/20 detailed reporters showed YoY growth averaging +38% (outliers TSS +66%, Bob's +16.8%), but 6 reported declines averaging -10% (Macy's -2.4% FY sales, Harte Hanks -13.9%), with margin compressions in 5/12 cases (-40bps avg, e.g., Macy's gross margin). Financials-specific patterns highlight REIT proxy focus on sustainability/insider policies (Seven Hills, ILPT) and bank merger risks, while forward-looking guidance flags upside (Protalix rev $78-83M 2026, Macy's Adj EPS $1.90-2.10). Critical developments: Strong 2025 beats (NRG EBITDA 167% target, Vistra Adj EBITDA +$112M), but going concern risks (Stardust $3.5M cash) imply selective opportunities in dividend payers and buyback leaders. Portfolio implications: Overweight financials with returns focus (avg dividend/buyback yield implied +5-7%), monitor Mar 26 bank votes for deal risks.

26 high priority 24 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 18, 2026

Across 50 SEC 8-K filings from March 18, 2026, a dominant theme is extensive leadership churn with 25+ instances of C-suite appointments, resignations, and restructurings (e.g., CEOs, CFOs, COOs), signaling both proactive team-building (positive in 12 cases) and potential instability (neutral/mixed in 13). Financing activities proliferate, including $300M term loans (FTI), $2.25B term loan (Phillips 66), $40M loan facility (Hyperfine), and share repurchases ($125M ASR ExlService, $200M Accelerant), indicating strong liquidity access amid neutral-to-positive sentiment in 70% of cases. M&A/divestitures highlight strategic shifts: TriMas $1.45B aerospace sale, Independent Bank $70.2M acquisition, Energy Fuels ASM deal amendment, and RocketFuel asset sales. Period-over-period data shows outliers like Accelerant FY2025 premium +35% YoY to $4.19B and EBITDA +149% to $282M, Ovid FY2025 revenue +1122% YoY to $7.3M with op ex -20% YoY, but GAAP losses widened sharply; no broad margin compression but mixed net income trends. Capital allocation leans shareholder-friendly with buybacks and no dividend cuts reported. Portfolio implications favor monitoring industrials/energy for deal catalysts and biotechs for trial advancements, with overall positive sentiment (avg materiality 7.4/10) suggesting sector rotation opportunities into stable leadership transitions.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 18, 2026

Across these 10 filings from the S&P 500 Technology stream (broadly including software, blockchain, semis, and adjacent), Micron Technology dominates with record Q2 FY2026 revenue of $23.86B (+75% QoQ, +196% YoY) and raised Q3 guidance to $33.5B ±$0.75B at 81% margins, signaling robust semiconductor demand. Contrasting sharply, dMY Squared reported widened net losses to $17.8M YoY amid surging G&A (+310%) and ballooning liabilities (+268% YoY), highlighting SPAC unwind risks. M&A and restructuring themes emerge with RocketFuel's non-binding asset sale term sheet retaining cash reserves, BlockchAIn's completed business combo unlocking AI/HPC data center revenue ($22.9M in 2024), and Creative Media's massive 261M+ share dilution for preferred redemptions. Capital allocation leans positive with Micron's 30% dividend hike to $0.15/share (record date March 30, 2026), while equity grants to ACNB execs and board elections/stability at Pineapple and ImmuCell add low-materiality positives. Period-over-period trends show 1/10 with explosive growth (Micron), 1/10 with sharp deterioration (dMY), and neutral restructuring in 3/10; no broad insider selling patterns, but interested-party transactions flagged. Sector implications point to AI/semiconductor strength amid blockchain/AI infra deals, but dilution and loss-making entities pressure smaller tech names.

7 high priority 3 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 18, 2026

Across 11 NASDAQ-100 related filings, standout performance from Micron Technology with record Q2 FY2026 revenue up 75% QoQ ($13.64B to $23.86B) and 196% YoY ($8.05B), driving 74.4% GAAP gross margins (up from 36.8% YoY) and a 30% dividend hike to $0.15/share, signaling robust semiconductor demand amid AI boom. Biotech and metals sectors show clinical and operational progress (MetaVia Phase 1 approval, ImmuCell board addition, Welsbach video), while Faraday Future's $500k employee share repurchase aligns management with shareholders. Dilution risks emerge in Creative Media & Community Trust's issuance of over 261M common shares for preferred redemptions, potentially pressuring stock price. Neutral shelf registrations (Critical Metals F-3) and governance updates (Pineapple, Community Trust) indicate routine capital access and stability. Portfolio-level trends reveal margin expansion outliers in semis (Micron +3,760 bps YoY gross margin) contrasting dilution in REITs; forward catalysts cluster in Q2-Q4 2026 for biotech data and dividends. Overall, bullish tech/semiconductor momentum outweighs dilution and neutral fundraising themes, with actionable buys in high-growth leaders.

3 high priority 8 medium 11 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 18, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (March 18, 2026 period), overarching themes include robust revenue growth in energy (Vistra exceeding EBITDA guidance by $112M, Energy Vault +341% YoY to $203.7M) and select retail/biotech sectors, contrasted by widespread margin compression (e.g., Home Depot operating income -2.9% YoY, Bob's Discount gross margin -110 bps to 45.7%) and persistent net losses in 12+ companies despite top-line gains. Portfolio-level trends show 18/50 filings with YoY revenue acceleration (avg +45% in high-growers like Accelerant +51.5%), but 15 report widening losses or equity erosion (e.g., Natural Resource net loss +2-6% YoY, cash at $0); capital returns remain strong with $5.75B Vistra buybacks since 2021 and dividends in banks like Great Southern $0.43/share. Critical developments: Biotech catalysts (Arvinas Phase 1 success >50% LRRK2 degradation), M&A progress (Two Harbors-UWM), and dilution risks (Creative Media 261M shares issued). Market implications favor energy/utilities outperformance amid strategic PPAs/acquisitions, while retail faces transaction declines (Home Depot -2.2% customers YoY); blue-chip stability via credit extensions (Hilton) signals resilience, but watch governance shifts and exec transitions in 10+ firms for conviction gauges.

33 high priority 17 medium 50 total filings